Aptevo Therapeutics Inc. (APVO)
| Market Cap | 139.43M |
| Revenue (ttm) | 10.97M |
| Net Income (ttm) | -18.87M |
| Shares Out | 3.23M |
| EPS (ttm) | -5.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $31.57 |
| Previous Close | $31.52 |
| Change ($) | 0.05 |
| Change (%) | 0.16% |
| Day's Open | 31.52 |
| Day's Range | 30.69 - 32.23 |
| Day's Volume | 55,943 |
| 52-Week Range | 3.11 - 48.36 |
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-onco...
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer.
LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumo...
Aptevo Therapeutics (APVO) news for Wednesday includes APVO stock taking a fall after a strong rally yesterday on clinical trial results. The post Aptevo Therapeutics News: Why APVO Stock Is F...
The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by 78.25% as it went from $6.30 at the close on Monday to $11.23 at the close on Tuesday. This is why it happened.
Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the m...
Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Is (APVO) Outperforming Other Medical Stocks This Year?
SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its p...
Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher on Tuesday, after the company announced it regained compliance with the NASDAQ listing requirements.
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today ...
Aptevo announced preliminary Q3'19 product revenue for its Hemophilia B drug IXINITY will be about $9M.
Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay
New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40
IXINITY revenue increased for the quarter, which is what I wanted to see.
Investors might want to pay attention to Aptevo Therapeutics over the next several weeks before the company's Q2 results.
About APVO
Aptevo Therapeutics, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinic... [Read more...]
| Industry Biotechnology | |
| CEO Marvin L. White | Employees 80 |
| Stock Exchange NASDAQ | Ticker Symbol APVO |
Financial Performance
In 2019, APVO's revenue was $32.42 million, an increase of 40.56% compared to the previous year's $23.07 million. Losses were -$40.45 million, -24.66% less than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for APVO stock is "Buy." The 12-month stock price forecast is 65.67, which is an increase of 108.01% from the latest price.